Steve Bryson, PhD, science writer —

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

Similar Outcomes for IPF Patients Found for Esbriet, Ofev in Analysis

People with idiopathic pulmonary fibrosis (IPF) had the same mortality and hospitalization rates, and incurred similar healthcare costs, whether they were treated with Esbriet (pirfenidone) or Ofev (nintedanib), a German insurance claims analysis showed. However, the analysis — conducted over five years and involving more than 1,000 patients…

Companies Partner With Goal of Treating PF, Other Fibrotic Disorders

Oncodesign and TiumBio have partnered to develop therapies for various diseases caused by fibrosis, or tissue scarring, including pulmonary fibrosis (PF). Under the collaboration, the French company Oncodesign will identify, produce, optimize, and conduct early stage analysis of therapeutic candidates generated from Nanocyclix — a technology…

NICE Agrees to Allow Ofev Therapy for Non-IPF Patients in UK

Clinicians in the U.K. will now be able to prescribe the antifibrotic medicine Ofev (nintedanib) to people with non-idiopathic pulmonary fibrosis (PF) under a new decision by the National Institute for Health and Care Excellence (NICE). That decision came following a five-year campaign led by the U.K. charity…

FSU Researcher Awarded $1.8M by NIH to Investigate Fibrotic Process

Research examining the role that protein-RNA interactions play in promoting pulmonary fibrosis (PF) and other related conditions is being accelerated by a $1.8 million grant from the National Institutes of Health (NIH). The funding, granted to Robert Silvers, PhD, a Florida State University (FSU) assistant professor of chemistry and…

Aria Reports Positive Preclinical Data for 2 New IPF Treatments

TXR-1002 and TXR-1007, two new therapeutic candidates for idiopathic pulmonary fibrosis (IPF) from Aria Pharmaceuticals, demonstrated significant efficacy at reducing tissue scarring and good tolerability in a mouse model of the disease. Moreover, Aria said, the new artificial intelligence approach its researchers used in the lab to identify and…

Serious Mortality, Ventilation Risk Seen in IPF Patients With COVID-19

People with idiopathic pulmonary fibrosis (IPF) infected with SARS-CoV-2, the virus that causes COVID-19, are at a greater risk of severe illness leading to mechanical ventilation or death than are infected patients without this progressive lung disease, a large database study reported. Among hospitalized individuals, however, its scientists saw…

Blood Levels Marking Collagen Turnover May Predict IPF Severity

The degree of collagen degradation, a process called collagen turnover, evident in a person’s blood at the time idiopathic pulmonary fibrosis (IPF) is diagnosed predicts the severity of disease progression within one year, regardless of antifibrotic treatment, a study reported. These findings support the use of collagen turnover as a blood…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums